Long-Term Disease Control With Second-Line Nivolumab Monotherapy in Malignant Pleural Mesothelioma: A Case Report

September 10, 2026 | Comments Off on Long-Term Disease Control With Second-Line Nivolumab Monotherapy in Malignant Pleural Mesothelioma: A Case Report

Cureus 2026 June 1 [Link] Shohei Otsuka, Kei Hiraoka, Nozomu Iwashiro Abstract Nivolumab is recommended as second-line therapy for malignant pleural mesothelioma (MPM); however, durable responses remain uncommon. In addition,…

Impact of CD73/CD155 Expression on Survival in Resected Epithelial Pleural Mesothelioma: A Retrospective Single-center Study

September 9, 2026 | Comments Off on Impact of CD73/CD155 Expression on Survival in Resected Epithelial Pleural Mesothelioma: A Retrospective Single-center Study

In Vivo 2026 July-August [Link] Yusuke Nabe, Yasuhiro Fujita, Teppei Hashimoto, Kanji Tanaka, Takehiko Manabe, Katsuma Yoshimatsu, Yukiko Nemoto, Natsumasa Nishizawa, Rintaro Oyama, Yohei Honda, Masataka Mori, Hiroki Matsumiya, Masatoshi…

Case Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma

September 8, 2026 | Comments Off on Case Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma

Frontiers in Oncology 2026 June 16 [Link] Zijuan Liu, Yating Yan, Caihong Jiang Abstract Background: Primary malignant pericardial mesothelioma (PMPM) is an exceedingly rare and highly malignant tumor that originates…

Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study

September 7, 2026 | Comments Off on Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study

Clinical Lung Cancer 2026 July 2026 July [Link] Rajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, Frank Griesinger, Martin Reck, Daniel C Christoph, Jonas Kuon, Nikolaj Frost, Christian Grohé, Martin Faehling,…

Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study

September 4, 2026 | Comments Off on Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study

Clinical Lung Cancer 2026 July [Link] Rajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, Frank Griesinger, Martin Reck, Daniel C Christoph, Jonas Kuon, Nikolaj Frost, Christian Grohé, Martin Faehling, Felix C…

Metastatic pleural mesothelioma presenting as ulcerated submucosal colonic nodules

September 3, 2026 | Comments Off on Metastatic pleural mesothelioma presenting as ulcerated submucosal colonic nodules

Journal of the American Association of Nurse Practitioners 2026 June 29 [Link] Shangwe Kiliaki, Kent Stevens Abstract Malignant pleural mesothelioma is a rare and aggressive malignancy associated with poor prognosis.…

An analysis of succinate dehydrogenase B in pleural mesothelioma

September 2, 2026 | Comments Off on An analysis of succinate dehydrogenase B in pleural mesothelioma

Discover Oncology 2026 June 23 [Link] Cormac J Jennings, Stefan J Marciniak, Giulia Pinton, Doris M Rassl, Laura Moro, Kenneth J O’Byrne, Robert C Rintoul, Stephen P Finn, Luciano Mutti,…

Dual-time-point [18F]FDG-PET/CT as a prognostic biomarker in patients with pleural mesothelioma undergoing immunotherapy

September 1, 2026 | Comments Off on Dual-time-point [18F]FDG-PET/CT as a prognostic biomarker in patients with pleural mesothelioma undergoing immunotherapy

EJNMMI Research 2026 June 20 [Link] Solfrid Thunold, Eivor Hernes, Lars Tore Gyland Mikalsen, Saima Farooqi, Åsa Kristina Öjlert, Roslyn J Francis, Anna K Nowak, Weronika Maria Szejniuk, Søren Steen…

Amivantamab Induces Immune-Mediated Cytotoxicity in Mesothelioma Through EGFR and MET Engagement

August 31, 2026 | Comments Off on Amivantamab Induces Immune-Mediated Cytotoxicity in Mesothelioma Through EGFR and MET Engagement

Journal of Thoracic Oncology 2026 June 20 [Link] Shinichiro Suzuki, Kaushal Parikh, Ezequiel Tolosa, Kuan-Li Wu, Rohini Mopuri, Jennifer Ayers-Ringler, Lin Yang, Kim P Lauer, Katherine E R Smith, Yan…

CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma

August 28, 2026 | Comments Off on CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma

Clinical Lung Cancer 2026 July [Link] Giulia Pasello, Daniela Scattolin, Eleonora Faccioli, Paolo Andrea Zucali, Giuseppe Marulli, Federica Grosso, Giovanni Luca Ceresoli, Marcello Tiseo, Alessandra Bearz, Fabiana Letizia Cecere, Luana…

Categories